Navigation Links
Queensland technology licensed by billion-dollar US company
Date:2/15/2008

University of Queensland scientists have developed a proprietary technology that will help other researchers in understanding fundamental aspects of growth, development, and disease, which has been licensed to one of the world's largest life science technology companies.

Dr Marcel Dinger and Professor John Mattick, from UQ's Institute for Molecular Bioscience, have designed a new type of microarray RNA chip, used by researchers to analyse which genes are being expressed at any one time in a particular cell.

The technology has been licensed through IMBcom, UQ's company for the commercialisation of intellectual property arising from research conducted at the IMB. It was licensed to Invitrogen, a provider of essential life science technologies for research, production and diagnostics with a 2006 revenue of US$1.15 billion.

Every cell in the body contains a full set of genes, but different cells express different subsets, Professor Mattick said. In the past these genes were thought only to code mainly for proteins, via the production of "messenger RNAs", but it is now evident that many other genes produce non-coding RNAs whose functions have yet to be determined.

It appears that we have misunderstood the nature of genetic programming in humans and other complex organisms, Professor Mattick said. Most of the genome is transcribed, mainly into non-coding RNAs, which appear to comprise a hidden layer of gene regulation whose full dimensions are just beginning to be explored.

There is increasing recognition that these non-coding RNAs control various levels of gene expression in physiology and development, as well as in the brain.

Products commercialized by Invitrogen will be based on a novel set of RNA probes that Dr Dinger and Professor Mattick have designed, which can uniquely identify tens of thousands of coding and non-coding RNA sequences. This is the first time that one product has been able to identify both large numbers of protein-coding and non-coding RNAs.

This technology will allow researchers to obtain more accurate information about the relationship between messenger and non-coding RNA expression, Dr Peter Isdale, CEO of IMBcom, said. It has the potential to make a real impact in cancer and stem cell research, as these RNAs are implicated in both of these areas.


'/>"/>

Contact: Bronwyn Adams
communications@uq.edu.au
61-733-462-134
Research Australia
Source:Eurekalert

Related medicine news :

1. Fluoridated water for Queensland ... at last
2. Queensland businessman is one in a million
3. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
4. Quantum light beams good for fast technology
5. New Smart Technology Makes Patient Data Collection Easier, More Efficient
6. Align Technology Executive to Present at Upcoming Financial Conferences
7. Pioneer Surgical Technology Hires Vice President of New Business Development
8. Purdue researchers develop technology to detect cancer by scanning surface veins
9. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
10. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
11. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... ... last week. In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds ... 2014. The company had 800 customers and 2,250 RCEs at the time of ...
(Date:2/26/2017)... ... February 25, 2017 , ... The February 13, 2017, assassination of Kim ... over nerve agents and the deadly use of chemical weapons. Many questions exist about ... even small doses can be lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing a new ... B2B Sellers will now only pay for B.A.N.T. quality sales leads based on the ... said, “Given the new reality that B2B buyers are controlling the sales process via ...
(Date:2/25/2017)... Viejo, CA (PRWEB) , ... February 25, 2017 , ... ... with ProSharpen Color tools from Pixel Film Studios. With ProSharpen Color users have total ... sliders to easily refine their color range. With color spectrum tools users can visually ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants implicated ... to eight genes that may explain why susceptibility to one of the disorders could ... study published today in the journal npj Schizophrenia. , “There is a wealth ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)...  International Biophysics Corporation, a global medical device manufacturer based ... 34% revenue growth in 2016 when compared to the previous ... growth was fueled by its AffloVest® sales in ... of its global sales of surgical product lines. ... enter our 25 th year in delivering high-quality, innovative ...
(Date:2/27/2017)... , Feb. 27, 2017  RegeneRx Biopharmaceuticals, ... clinical-stage drug development company focused on tissue protection, ... for RGN-137, GtreeBNT Co., Ltd., received a positive ... 3 clinical trial design for RGN-137 to treat ... healing gel that incorporates Thymosin beta 4 ("Tß4") ...
(Date:2/27/2017)... Leading Countries, Technologies and Companies The global ... CAGR of 8.9% from 2016-2021 and CAGR of 9.2% from 2021-2027. ... from 2016 to 2027. The market is estimated at $816m in ... ... to discover how you can exploit the future business opportunities emerging ...
Breaking Medicine Technology: